Brain Metastases Clinical Trials in New York, New York

5 studies are recruiting for brain metastases in New York, New York right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

1. Phase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive Malignancies

   BDTX-4933-101 is a first-in-human, open-label, Phase 1/2 dose escalation, dose optimization and expansion study designed to evaluate the safety and tolerability of S241656 as monotherapy and in combination with other anti-cancer therapies in participants with selected advanced malignancies. The stu…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   NYU Langone Medical Center - Perlmutter Cancer Center (NYU Cancer Institute), New York, New York

   Locations

   49 in total

   Run by

   Institut de Recherches Internationales Servier

   See if you can join NCT05786924 on ClinicalTrials.gov

2. A Study of Stereotactic Radiosurgery (SRS) for People With Lung Cancer That Has Spread to the Brain

   The purpose of the study is to see if stereotactic radiosurgery/SRS is an effective treatment for people with a new diagnosis of brain metastases from small cell lung cancer/SCLC.

   Stage

   Phase 2

   Ages

   18 and older

   Site

   Memorial Sloan Kettering Cancer Center (All Protocol Activities), New York, New York

   Locations

   7 in total

   Run by

   Memorial Sloan Kettering Cancer Center

   See if you can join NCT05419076 on ClinicalTrials.gov

3. Pembrolizumab And Stereotactic Radiosurgery (Srs) Of Selected Brain Metastases In Breast Cancer Patients

   Patients with metastatic breast cancer with at least 2 brain metastases will receive pembrolizumab every 3 weeks. Patients will undergo stereotactic radiosurgery (SRS) to one of the brain lesions. Pembrolizumab infusion will be given on Day 4 (+/-1) after SRS treatment at the standard dose of 200mg…

   Stage

   Phase 1

   Ages

   19 to 90

   Site

   Weill Cornell Medicine, New York, New York

   Locations

   3 in total

   Run by

   Weill Medical College of Cornell University

   See if you can join NCT03449238 on ClinicalTrials.gov

4. Developing a New MRI Technique to Understand Changes in Brain Tumors After Treatment

   The purpose of this study is to develop and test a new magnetic resonance imaging (MRI) technique to see if it can be used to tell the difference between tumor growth from worsening of cancer and growth from the effects of treatment in participants who have brain tumors treated with radiation thera…

   Stage

   Not phased

   Ages

   18 and older

   Site

   Memorial Sloan Kettering Cancer Center (All Protocol Activities), New York, New York

   Run by

   Memorial Sloan Kettering Cancer Center

   See if you can join NCT05559853 on ClinicalTrials.gov

5. Brain [18F]-FES PET/CT in Patients With Estrogen-Receptor Positive Breast Cancer

   The goal of this interventional study is to optimize the protocol of FES PET/CT in Estrogen Receptor positive Breast cancer patients with Brain metastases. Patients will undergo MRI of the brain and FDG PET/CT brain as part of standard of care for radiation treatment planning. An additional 18F-FES…

   Stage

   Phase 4

   Ages

   18 and older

   Site

   New York-Presbyterian/Weill Cornell Medical Center, New York, New York

   Run by

   Weill Medical College of Cornell University

   See if you can join NCT06072807 on ClinicalTrials.gov